8-K: BiomX Inc. Announces 1-for-10 Reverse Stock Split

BiomX Inc. will implement a 1-for-10 reverse stock split of its common stock and units, effective August 26, 2024.

Summary

• BiomX Inc. has announced a 1-for-10 reverse stock split of its common stock and units.
• The reverse stock split was approved by the Board of Directors on August 8, 2024.
• The reverse stock split will be effective at 12:01 a.m. Eastern Time on August 26, 2024.
• Trading on a split-adjusted basis will begin on the NYSE American at the start of trading on August 26, 2024.
• Every ten shares of old common stock will be converted into one share of new common stock.
• The new common stock will have a new CUSIP number of 09090D 301.
• No fractional shares will be issued; instead, fractional shares will be rounded up to the next whole share.
• The company's outstanding warrants and equity awards will be adjusted accordingly.
• The units will also undergo a 1-for-10 reverse split and will trade under the existing symbol PHGE U with a new CUSIP number of 09090D 400.
• The total number of authorized shares will remain unchanged.

Sentiment

Score: 5

Explanation: The document describes a reverse stock split, which is a neutral event. It is not inherently positive or negative, but rather a corporate action to manage share price and listing requirements. The sentiment is therefore neutral.

Positives

• The reverse stock split is intended to increase the per-share trading price of the company's stock.
• The rounding up of fractional shares ensures that all shareholders receive a whole number of shares.

Negatives

• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
• The reverse stock split does not change the underlying value of the company.

Risks

• The reverse stock split may not achieve the desired increase in share price.
• There is a risk that the stock price could decline after the reverse split.
• The company's future performance is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company expects the common stock and units to begin trading on a split-adjusted basis on August 26, 2024.

Management Comments

• The Board of Directors determined the 1-for-10 reverse stock split to be in the best interests of the corporation and its stockholders.

Industry Context

Reverse stock splits are often used by companies to increase their stock price to meet minimum listing requirements or to make the stock more attractive to institutional investors. This is a common practice in the biotech industry.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies, particularly in the biotech sector, to maintain listing compliance or improve share price perception.
• Many companies in similar situations, such as those facing delisting risks or seeking to attract institutional investors, have implemented reverse stock splits.
• For example, companies like Agenus Inc. and Ocugen Inc. have also recently undergone reverse stock splits to manage their share price.

Stakeholder Impact

• Shareholders will have their shares consolidated at a 1-for-10 ratio.
• Shareholders holding fractional shares will receive an additional fraction of a share to round up to the next whole share.
• The reverse stock split may impact the perceived value of the company's stock.

Next Steps

• The company will file the Certificate of Amendment with the Secretary of State of Delaware.
• The common stock and units will begin trading on a split-adjusted basis on August 26, 2024.
• Continental Stock Transfer & Trust Company will send instructions to stockholders of record regarding the exchange of certificates.

Key Dates

Keywords

reverse stock split, common stock, units, share consolidation, stock split, BiomX, PHGE, NYSE American